Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.

Kostev, Karel; Pscherer, Stefan; Rist, Roland; Busch, Stefan; Scheerer, Markus F

Kostev, Karel; Pscherer, Stefan; Rist, Roland; Busch, Stefan; Scheerer, Markus F.

Affiliation

Kostev K; 1 IMS Health, Frankfurt am Main, Germany.
Pscherer S; 2 Sophien- und Hufeland-Klinikum, Weimar, Germany.
Rist R; 3 AstraZeneca GmbH, Wedel, Germany.
Busch S; 3 AstraZeneca GmbH, Wedel, Germany.
Scheerer MF; 3 AstraZeneca GmbH, Wedel, Germany.

J Diabetes Sci Technol ; 11(3): 590-596, 2017 05.

Article in En | MEDLINE | ID: mdl-28300454

Subject(s)

Benzhydryl Compounds/therapeutic use; Body Weight/drug effects; Diabetes Mellitus, Type 2/drug therapy; Glucosides/therapeutic use; Glycated Hemoglobin/analysis; Hypoglycemic Agents/therapeutic use; Aged; Blood Glucose/drug effects; Female; Humans; Insulin Glargine/therapeutic use; Male; Middle Aged; Primary Health Care; Retrospective Studies

Key words

HbA1c; body mass index; dapagliflozin; insulin; type 2 diabetes

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzhydryl Compounds / Body Weight / Glycated Hemoglobin / Diabetes Mellitus, Type 2 / Glucosides / Hypoglycemic Agents Type of study: Observational_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Diabetes Sci Technol Journal subject: ENDOCRINOLOGIA Year: 2017 Type: Article Affiliation country: Germany

Fulltext

XML

PubMed Links

Search on Google